Revvity, Inc. Stock price

Equities

RVTY

US7140461093

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 03:19:00 2024-03-28 pm EDT 5-day change 1st Jan Change
105.4 USD +0.03% Intraday chart for Revvity, Inc. +0.45% -3.44%
Sales 2024 * 2.82B Sales 2025 * 3.01B Capitalization 13.02B
Net income 2024 * 277M Net income 2025 * 340M EV / Sales 2024 * 5.41 x
Net Debt 2024 * 2.21B Net Debt 2025 * 1.81B EV / Sales 2025 * 4.92 x
P/E ratio 2024 *
47.1 x
P/E ratio 2025 *
38.2 x
Employees 11,500
Yield 2024 *
0.26%
Yield 2025 *
0.26%
Free-Float 99.71%
More Fundamentals * Assessed data
Dynamic Chart
Revvity Files Lawsuit Against Partner Cloud Software Group, Reaffirms 2024 Guidance MT
Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024 CI
Transcript : Revvity, Inc. Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 09:00 AM
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication CI
Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research CI
Transcript : Revvity, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM
Transcript : Revvity, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 09:15 AM
Transcript : Revvity, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:10 AM
Transcript : Revvity, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 08:00 AM
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions CI
Revvity Insider Sold Shares Worth $3,841,563, According to a Recent SEC Filing MT
Revvity Insider Sold Shares Worth $1,613,697, According to a Recent SEC Filing MT
KeyBanc Ups Price Target on Revvity to $126 From $110, Keeps Overweight Rating MT
Raymond James Raises Price Target on Revvity to $127 From $106, Maintains Outperform Rating MT
Job data is good for the economy, not for rate cuts Our Logo
More news
1 day+1.92%
1 week+0.71%
Current month-3.81%
1 month-0.21%
3 months-4.77%
6 months-3.34%
Current year-3.57%
More quotes
1 week
102.33
Extreme 102.33
105.66
1 month
102.33
Extreme 102.33
111.18
Current year
100.16
Extreme 100.16
115.00
1 year
79.50
Extreme 79.5
139.04
3 years
79.50
Extreme 79.5
203.16
5 years
62.91
Extreme 62.91
203.16
10 years
38.96
Extreme 38.96
203.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 14-04-30
Director of Finance/CFO 35 18-09-30
Chief Tech/Sci/R&D Officer - 23-04-30
Members of the board TitleAgeSince
Chairman 66 00-12-31
Director/Board Member 57 17-10-29
Director/Board Member 70 16-07-26
More insiders
Date Price Change Volume
24-03-28 105.5 +0.13% 269 696
24-03-27 105.4 +1.92% 1,224,431
24-03-26 103.4 +0.41% 684,130
24-03-25 103 -0.24% 864,491
24-03-22 103.2 -1.73% 852,178

Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT

More quotes
Revvity, Inc. (formerly PerkinElmer, Inc.) specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales (including intragroup) break down by family of products as follows: - medical diagnosis equipment (61%); - analytical tools and instruments (39%): biological molecular research tools, thermal analysis software, chemical and environmental measurement tools, genetic screening instruments, reagents, etc. Net sales are distributed geographically as follows: the United States (46.7%), China (14.4%), the United Kingdom (4.1%) and other (34.8%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
105.4 USD
Average target price
123.1 USD
Spread / Average Target
+16.79%
Consensus
  1. Stock
  2. Equities
  3. Stock Revvity, Inc. - Nyse